Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

NCT06406465 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT06406465
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06406465 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
October 19, 2026
Completion date
July 30, 2028
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

carcinoma, neuroendocrine, neuroendocrine; carcinoma, small cell; receptors, tumor, neuroendocrine, tumors, neuroendocrine